<DOC>
	<DOCNO>NCT02319187</DOCNO>
	<brief_summary>Esophageal cancer highly aggressive malignancy poor overall outcome . The purpose study evaluate progression free survival safety irinotecan plus S1 versus S1 alone patient previously treat advanced esophageal cancer</brief_summary>
	<brief_title>Irinotecan Plus S1 Versus S1 Patients With Previously Treated Advanced Esophageal Cancer : ESWN 01 Trial</brief_title>
	<detailed_description>Two arm , phase 3 study irinotecan plus S1 versus S1 alone previously treat patient recurrent metastatic esophageal cancer . 240 Patients enrolled trial . The primary objective study determine PFS two arm . One arm follow : irinotecan 160 mg/m2 administer intravenous infusion 60 minute Days 1 , follow S1 80mg 120 mg per day Days 1-10 , every 14 day per cycle . The arm S1 80mg 120 mg per day Days 1-14 , every 21 day per cycle.This study also include investigation UGT1A1polymorphisms study population .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically proven esophageal squamous cell carcinoma ; 18 ≤ age ≤ 70 ; ECOG 02 ; Previously Treated platinum paclitaxel base regimen ; Unidimensionally measurable disease ( CT MRI per RECIST ) ; Patients project life expectancy least 3 month ; Completion baseline quality life questionnaire Adequate bone marrow function ( ANC ≥ 1,500/ul , blood platelet ≥ 100,000/ul , haemoglobin ≥ 10g/dl ) ; Adequate renal function ( serum creatinine ≤ 1.5mg/dl ) liver function ( serum bilirubin ≤ 1.5UNL , AST/ALT ≤ 3 time ( normal value ) Written inform consent Previous chemotherapy 5FU irinotecan recurrence metastasis ; adjuvant chemotherapy 5FUbased chemotherapy within 6 month prior start study treatment ; Active infection require antibiotic Pregnant , lactate woman Psychiatric illness , epileptic disorder Concurrent systemic illness appropriate chemotherapy History malignancy within 5 year except nonmelanoma skin cancer , cervix situ carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Esophageal Neoplasms</keyword>
</DOC>